Prostate Cell News Volume 9.19 | May 25 2018

TOP STORY

High-Throughput Screening of Prostate Cancer Risk Loci by Single Nucleotide Polymorphisms Sequencing

Scientists report a high-throughput single-nucleotide polymorphisms (SNPs) sequencing technology to simultaneously screen hundreds to thousands of SNPs for their allele-dependent protein-binding differences. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling

High-fat diet increased myeloid-derived suppressor cells and accelerated prostate cancer tumor growth via IL6/pSTAT3 signaling in mice. [Clin Cancer Res] Abstract

Entrapment of Prostate Cancer Circulating Tumor Cells with a Sequential Size-Based Microfluidic Chip

The authors describe a new size-based, multiple-row cancer cell entrapment device that captured LNCaP-C4-2 prostate cancer cells with >95% efficiency when in spiked mouse whole blood at ~50 cells/mL. [Anal Chem] Abstract

Phosphatidylinositol 3-Kinase β and δ Isoforms Play Key Roles in Metastasis of Prostate Cancer DU145 Cells

Researchers investigated the change in migratory and invasive ability of DU145 cells after treatment with each phosphatidylinositol 3-kinase isoform-specific inhibitor. [FASEB J] Abstract

SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer

Sterol regulatory element binding transcription factor 1 (SREBF1) recruitment to regulatory regions of its target genes was induced upon treatment with the synthetic androgen R1881, an effect abrogated upon inhibition of the mTOR signaling pathway. In turn, pharmacological and genetic inhibition of SREBF1 activity impaired the androgen-mediated induction of the key lipogenic genes fatty acid synthase and stearoyl-CoA desaturase. [Mol Cancer Res] Abstract

AIRE Promotes Androgen-Independent Prostate Cancer by Directly Regulating IL-6 and Modulating Tumor Microenvironment

Researchers showed that autoimmune regulator (AIRE) finds differential expression in androgen-dependent and -independent prostate cancer cells. AIRE expression was more in androgen-independent cells due to its regulation by transcription factor Elk-1. These enhanced levels of AIRE modulated the prostate tumor microenvironment by transcriptionally activating a malignancy gene IL-6 in androgen-independent cells. [Oncogenesis] Full Article

Stromal Gli Signaling Regulates the Activity and Differentiation of Prostate Stem and Progenitor Cells

Blockade of stromal Gli signaling inhibited prostate tissue regeneration in vivo. The inhibition of stromal Gli signaling suppressed the differentiation of basal and progenitor cells to luminal cells, and limited prostate tubule secretory capability. Stromal cells were able to compensate for the deficiency of epithelial sonic hedgehog signaling in prostate tissue regeneration. [J Biol Chem] Abstract | Full Article

Growth Hormone-Releasing Hormone Antagonists Reduce Prostatic Enlargement and Inflammation in Carrageenan-Induced Chronic Prostatitis

In vitro, GHRH stimulated multiple pathways involved in inflammation and growth in both benign prostatic hyperplasia‐1 and PrEp cells including NFκB p65, AKT, ERK1/2, EGFR, STAT3 and increased the levels of TGF‐β1 and snail/slug. GHRH also stimulated the transactivation of the IGF receptor. [Prostate] Abstract

Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells

Scientists demonstrated significant dose- and time-dependent UCM 1037 antiproliferative effects in androgen-sensitive LNCaP and 22Rv1 cells. They also revealed that UCM 1037 down-regulates androgen receptor levels and Akt activation in LNCaP and 22Rv1 cells. [Int J Mol Sci] Full Article

Targeting Prostate Cancer: Prostate‐Specific Membrane Antigen Based Diagnosis and Therapy

As prostate‐specific membrane antigen is highly overexpressed on malignant prostate tumor cells and as its expression rate correlates with the aggressiveness of the disease, this tumor‐associated biomarker provides the possibility to develop new strategies for diagnostics and therapy of prostate cancer. [Med Res Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

ERLEADA^™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson presented a post-hoc analysis from the Phase III SPARTAN study that showed treatment with ERLEADA^™ significantly reduced the risk of PSA progression in patients with non-metastatic castration-resistant prostate cancer who had a rapidly rising PSA while receiving continuous androgen deprivation therapy. [Press release from Janssen Global Services, LLC discussing research presented at the 2018 American Urological Association (AUA) Annual Meeting, San Francisco] Press Release

Finasteride Safe, Long-Term Results Show

Twenty five years after it opened for enrollment, the landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens’ risk of getting prostate cancer without increasing their risk of dying from the disease. [Press release from SWOG discussing research presented at the 2018 American Urological Association (AUA) Annual Meeting, San Francisco] Press Release

Sun Pharma Announces USFDA Approval of YONSA^® (Abiraterone Acetate) to Treat Metastatic Castration-Resistant Prostate Cancer in Combination with Methylprednisolone

Sun Pharmaceutical Industries Ltd. and Churchill Pharmaceuticals, LLC. announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the FDA for YONSA^®, a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer. [Sun Pharmaceutical Industries Ltd. (Business Wire Inc.)] Press Release

Sotio Starts Phase I/II Trial of DCVAC in Combination with ONCOS-102: The Targovax Adenovirus Based Immunotherapy

SOTIO announced that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming engineered human serotype 5 adenovirus, for patients with prostate cancer. [SOTIO] Press Release

Italy’s New Prime Minister Defended Discredited Stem Cell Therapy

The electoral victory of two populist parties in March had Italian scientists worried that a new era of antiscientific policies might be around the corner—and appointment of Giuseppe Conte as the country’s new prime minister is making some even more nervous. [ScienceInsider] Editorial

Scientist Who Received Millions from NIH Leaves Alabama Posts

A professor who received about $5 million in grants from the National Institutes of Health left his posts at the University of Alabama, Birmingham, and Birmingham VA Medical Center last year after an investigation found evidence of image manipulation in 20 of his papers, Retraction Watch has learned. [The Scientist] Editorial

Plans for £100M Nobel Centre Blocked by Swedish Court

A Swedish court has blocked the construction of a major new Nobel Centre in Stockholm intended as the future venue for the world’s most prestigious arts and science awards. [The Guardian] Editorial

PM Will Pay to Have ‘Full Association’ with EU Research

The Prime Minister made the strongest commitment yet to “fully associate” the UK with the EU’s £68bn research program post-Brexit. Theresa May said the UK would be willing to make “an appropriate contribution” and in return it would expect a “suitable level of influence”. [BBC News] Editorial

NEW The New York Stem Cell Foundation (NYSCF) Conference
October 23-24, 2018
New York, New York, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Steroid Hormone Production and Signaling (University of Rochester Medical Center)

Postdoctoral Positions – Transcriptional/Epigenetic Regulation in Cancer Progression (UT Health San Antonio)

Postdoctoral Fellow/Research Scientists – Prostate Cancer Research (Institute of Oncology Research – Universita della Svizzera Italiana)

Postdoctoral Position – Drug Discovery for Advance Prostate Cancer (Lerner Research Institute – Cleveland Clinic)

Postdoctoral Fellow – Computational Genomics of Cancer (Cold Spring Harbor Laboratory)

Research Associate – Computational Biology (University College London)

Academic Position – Cancer Research (Cedars-Sinai Medical Center)

Tenure-Track Faculty Position – Cancer Research (University of Ottawa)

Postdoctoral Fellow – Prostate Cancer (Moffitt Cancer Center)

Postdoctoral Associate – Prostate Research (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.